Description
Product Overview: SS-31 (Elamipretide / Szeto-Schiller Peptide)
SS-31 (Elamipretide / MTP-131) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) engineered to selectively concentrate at the inner mitochondrial membrane (IMM). By binding electrostatically and hydrophobically to cardiolipin—a unique phospholipid exclusive to the IMM—SS-31 restores mitochondrial cristae structure, optimizes electron transport chain efficiency, and suppresses pathological reactive oxygen species (ROS) production. SS-31 serves as a premier research compound for studying cellular bioenergetics, mitochondrial dysfunction, ischemia-reperfusion injury, and age-related metabolic decay.
Primary Research Applications & Reasons for Study
- Cardiolipin Targeting & Structural Repair: Selectively binding to oxidized or damaged cardiolipin to normalize membrane curvature and rebuild inner mitochondrial cristae architecture.
- Electron Transport Chain Efficiency: Optimizing supercomplex assembly and cytochrome c interactions to maximize ATP production while dampening electron leakage.
- Mitochondrial ROS Scavenging: Directly neutralizing intracellular free radicals at their primary source of origin before oxidative damage triggers cellular necrosis or apoptosis.
- Ischemia-Reperfusion & Organ Protection: Evaluating organ transplantation preservation, renal ischemic tissue models, and cardiac failure protocols characterized by severe mitochondrial breakdown.
Expected Research Results & Timeline Metrics
-
Phase 1 / Hours 1–24
Rapid IMM Localization: Immediate concentration within the inner mitochondrial membrane, high-affinity cardiolipin binding, and acute drop in mitochondrial ROS emission. -
Phase 2 / Weeks 1–3
Cristae Stabilization & Elevated ATP Yields: Statistically significant increases in cellular ATP output, reduced cytochrome c release into the cytosol, and improved cellular survival under ischemic stress assays. -
Phase 3 / Weeks 4–8
Systemic Tissue Bioenergetic Recovery: Reversal of age-related mitochondrial dysfunction, decreased fibrotic remodeling in cardiac/renal injury models, and restored exercise capacity parameters in neuromuscular disease models.
Key Research Benefits
- Mitochondria-Selective Targeting: Concentration up to 5,000-fold higher inside the inner mitochondrial membrane compared to cytosolic levels without relying on membrane potential gradient.
- Direct Cardiolipin Protection: Prevents cardiolipin peroxidation, stabilizing the structural integrity of respiration supercomplexes.
- Reverses Energetic Failure: Restores electron transport chain efficiency to reverse metabolic exhaustion in aging and ischemia models.
- Gold-Standard Bioenergetic Model: Indispensable control compound for metabolic, cardiovascular, renal, and neurodegenerative disease research.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.